$HTBX
Heat Biologics Inc
PRICE
$2.38 -
Extented Hours
VOLUME
110,045
DAY RANGE
2.33 - 2.48
52 WEEK
2.07 - 10.85
Join Discuss about HTBX with like-minded investors
@JPwhoisbrown #droscrew
they'd like to stop the bleeding that -44% > @dros said: New option listings for 5/3 include 1stdibs com Inc ($DIBS), Leo Holdings III Corp ($LOCL), Paragon 28 Inc ($FNA), NHWK Stock ($NHWK), and SMR Stock ($SMR). Option delistings effective 5/3 include Heat Biologics ($HTBX) and Spring Valley Acquisition Corp ($SV).
83 Replies 8 š 12 š„
@dros #droscrew
New option listings for 5/3 include 1stdibs com Inc ($DIBS), Leo Holdings III Corp ($LOCL), Paragon 28 Inc ($FNA), NHWK Stock ($NHWK), and SMR Stock ($SMR). Option delistings effective 5/3 include Heat Biologics ($HTBX) and Spring Valley Acquisition Corp ($SV).
45 Replies 8 š 14 š„
@Milpower1967 #ivtrades
Own 485 shares at $11.20. Sold covered calls and now selling 3/19 puts @.70. Am seeing this price level as bottom/near bottom and am good with taking 10% on the puts.
40 Replies 7 š 11 š„
@Milpower1967 #ivtrades
Well, my MAX rule is 10% and I did not violate that, BUT I am violating my max loss rule. Bye about 20%. The options are far enough out to pay IF SNDL recovers. $HTBX is not a shitty company or stock, so am going to wait it out. Other plays are slowly working. I'm not a gambler with stocks (or stonks).
113 Replies 6 š 10 š„
@maletone #StockTraders.NET
I didn't trade it... I just traded 3 names $SNDL, $HTBX & $ITRM
107 Replies 12 š 13 š„
Key Metrics
Market Cap
61.05 M
Beta
0.91
Avg. Volume
165.82 K
Shares Outstanding
25.65 M
Yield
0%
Public Float
0
Next Earnings Date
Next Dividend Date
Company Information
Heat Biologics is a biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system. The company's gp96 platform is designed to activate immune responses against cancer or infectious diseases. The Company has multiple product candidates in development leveraging the gp96 platform, including HS-110, which has completed enrollment in its Phase 2 trial, and a COVID-19 vaccine program in preclinical development. In addition, Heat Biologics is also developing a pipeline of proprietary immunomodulatory antibodies and cell-based therapies, including PTX-35 and HS-130 in Phase 1 clinical trials.
CEO: Jeffrey Wolf
Website: www.heatbio.com
HQ: 627 Davis Drive Morrisville, 27560 North Carolina
Related News